60 Degrees Pharmaceuticals (SXTP) Reports PCR-Negative Outcomes in 5 Babesiosis Patients
60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.
How this was made
The 30-second read
Why it matters
The disclosed results provide the first public efficacy signal for this regimen, potentially influencing FDA discussions on accelerated approval pathways.
Market read
First report of positive trial data could lift SXTP stock and affect peer biotech valuations.
What to watch
Regulatory acceptance of NAT negativity as a surrogate endpoint remains uncertain.
Background
60 Degrees Pharmaceuticals is a clinical‑stage biotech focused on treatments for parasitic infections. The expanded access study evaluates a tafenoquine–atovaquone regimen for babesiosis.
Ticker impact
The company reported that all five completed patients in its expanded access study showed clinical improvement and negative PCR results for Babesia, with 4/5 also negative on NAT testing.
likely upward pressure as market prices in the favorable efficacy signal and regulatory catalyst potential
First disclosure of trial outcomes; data are favorable and could de‑risk the FDA approval timeline.
Market effects
May improve outlook for biotech firms developing anti‑parasitic therapies.
Limited to U.S. biotech sector.
Modest; relevance confined to investors tracking early‑stage infectious‑disease pipelines.
Counterpoint
Data set is very small (5 patients) and uncontrolled; market may overreact to limited evidence.
Key entities
- company60 Degrees Pharmaceuticals
Biotech developer of the tafenoquine–atovaquone regimen.
